Newsable Asianet News on MSN4h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...
As more research is published about the health benefits associated with GLP-1s, like sleep apnea, heart disease, and ...
More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
Since the early 1960s our obesity rates have tripled. Now 60% of adults and 15% of children and adolescents are overweight or ...
New letters urge the Centers for Medicare & Medicaid Services to expand Medicare and Medicaid to include FDA-approved ...
Some of the best health care stocks for February 2025, based on 30-day returns, include Akero Therapeutics Inc., Guardant Health Inc., and Inari Medical Inc. The best-performing health care stocks in ...
In its current form, SNAP operates as a de facto subsidy program that props up some of the unhealthiest parts of the food ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback